To explore the resistance of myeloma cells to chemo- and immuno- therapeutic drugs and the risk of tumor relapse in a simulated bone marrow microenvironment, we modeled the outcomes from the treatments with BTZ, LEN, and Thal, respectively. The gene discussed is CASC3; the disease is plasma cell myeloma.